CClinicalTrials.gg
CompletedNCT00658138Updated Oct 2, 2024Results posted

Clinical Evaluation of 3M™ ESPE™ Adper™ Scotchbond™ SE Self-Etch Adhesive in Class I and Class II Restorations in Adults

An interventional study of 3M ESPE Adper Scotchbond SE and 3M ESPE Adper Scotchbond 1XT in Dental Caries, sponsored by Solventum US LLC. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-02.

Sponsored by Solventum US LLC · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the performance of a new dental adhesive system in the restoration of Class I and Class II cavities in adult teeth.

02

Conditions studied

  • Dental Caries

Browse trials for

03

In context

Dental Caries

1,109 studies on the registry are indexed under Dental Caries; 197 are open to participants now.

This study's enrollment of 61 is close to the median of 60 across 916 interventional studies indexed under Dental Caries.

Browse Dental Caries studies →

Lead sponsor

Solventum US LLC is the lead sponsor of 62 studies on the registry; 2 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Must be at least 18 years of age
  • Must have 2 or 4 qualifying Class I or Class II cavities
  • Must be willing to sign consent form
  • Must be willing to return to University dental clinic for 4 study appointments
  • Must be in good medical health and able to tolerate dental procedures

Exclusion criteria

Exclusion Criteria:

  • Current participation in other restorative product studies
  • Known allergies to dental products
  • Unacceptable level of oral hygiene
  • Chronic periodontitis (gum disease)
  • Rampant caries (cavities)
  • Severe salivary gland problems
  • Inability or unwillingness to attend study appointments
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Adhesive A

    Device: 3M ESPE Adper Scotchbond SE

  • Active comparator
    Adhesive B

    Device: 3M ESPE Adper Scotchbond 1XT

Interventions

  • Device3M ESPE Adper Scotchbond SE

    To be used per manufacturer's instructions.

    Also known as: Dental adhesive used for bonding fillings

  • Device3M ESPE Adper Scotchbond 1XT

    To be used per manufacturer's instructions.

    Also known as: Dental adhesive used for bonding fillings

06

What researchers measure

Primary outcomes

  1. Percentage of Restorations Scoring Alpha

    Restorations were scored Alpha, Bravo or Charlie for retention, post-operative sensitivity, anatomic form, margin integrity, color match, stain resistance, and secondary caries. Alpha score = 'excellent' Bravo = 'acceptable' Charlie = 'unsatisfactory'. Total Alpha scores were evaluated for the primary outcome.

    Time frame: 12 months

07

Results

Posted Mar 26, 2012
Limitations and caveats
Main limitation of study was small sample size and short duratrion. Study was a pilot of one year's duration.

Participant flow

61 subjects were recruited from 70 patients with a total of 134 study teeth. Recruitment was from December 2008 to April 2009. Subjects were recruited from patients attending PI's clinic

Participant flow — Overall Study
Milestone3M ESPE Adper Scotchbond SE and 3M ESPE Adper Scotchbond 1XT
Started61
Completed40
Not completed21

Outcome measures

PrimaryPercentage of Restorations Scoring Alpha

Restorations were scored Alpha, Bravo or Charlie for retention, post-operative sensitivity, anatomic form, margin integrity, color match, stain resistance, and secondary caries. Alpha score = 'excellent' Bravo = 'acceptable' Charlie = 'unsatisfactory'. Total Alpha scores were evaluated for the primary outcome.

Time frame:
12 months
Reported as:
Number · percentage of Alpha scores
Percentage of Restorations Scoring Alpha
percentage of Alpha scoresScotchbond SEScotchbond 1XT
Percentage of Restorations Scoring Alpha10096
Statistical analysis
  • Scotchbond SE vs Scotchbond 1XT · Wilcoxon (Mann-Whitney) · p = 0.05 · Mean difference (final values): 0.05
  • Scotchbond SE vs Scotchbond 1XT · Wilcoxon (Mann-Whitney) · p = >0.05

Adverse events

Collected over One year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3M ESPE Adper Scotchbond SE and 3M ESPE Adper Scotchbond 1XT—0/61 (0%)0/61 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)3M ESPE Adper Scotchbond SE and 3M ESPE Adper Scotchbond 1XT
<=18 years0
Between 18 and 65 years61
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)3M ESPE Adper Scotchbond SE and 3M ESPE Adper Scotchbond 1XT
Female34
Male27
Region of Enrollment
Region of Enrollment(participants)3M ESPE Adper Scotchbond SE and 3M ESPE Adper Scotchbond 1XT
Italy61
08

Study locations

1 site
  • University of Bologna, Clinica Odontoiatrica
    Bologna, Italy
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00658138
Lead sponsor
Solventum US LLC
Collaborators
3M
Responsible party
Sponsor
First posted
Apr 14, 2008
Start date
Dec 2008
Primary completion
Nov 2010
Completion
Dec 2011
Results posted
Mar 26, 2012
Last update
Oct 2, 2024

Study contacts

Giovanni Dondi dall'Orologio, Professor
principal investigator · University of Bologna

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion